

ADVERTISEMENT

Read our Commission addressing the challenges of COPD care delivery in the USA

THE LANCET
Respiratory Medicine

[Home](#) [Journals](#) [Specialties](#) [The Lancet Clinic](#) [Global Health](#) [Multimedia](#) [Campaigns](#) [More](#) [Information for](#)
[Submit a Paper](#)

THE LANCET
Respiratory Medicine



[Login](#) | [Register](#) | [Claim Your Subscription](#) | [Subscribe](#)

[Online First](#) [Current Issue](#) [All Issues](#) [Multimedia](#) [About the Journal](#) [Advisory Board](#)

[All Content](#)

[Search](#) [Advanced Search](#)

[< Previous Article](#)

Volume 6, No. 2, p97–106, February 2018

[Next Article >](#)

Access this article on [ScienceDirect](#)

Articles

Oral prednisolone in preschool children with virus-associated wheeze: a prospective, randomised, double-blind, placebo-controlled trial

S J Foster, MBBS, M N Cooper, BSc, S Oosterhof, MBBS, M L Borland, MBBS

Published: 15 January 2018

PlumX Metrics



- Mentions
 - News Mentions: 1
- Social Media
 - Tweets: 138
- Citations
 - Citation Indexes: 1

[see details](#)

DOI: [https://doi.org/10.1016/S2213-2600\(18\)30008-0](https://doi.org/10.1016/S2213-2600(18)30008-0)

Article Options

[PDF \(680 KB\)](#)
 [Download Images\(.ppt\)](#)

[Email Article](#)
 [Add to My Reading List](#)
 [Export Citation](#)
 [Create Citation Alert](#)
 [Cited by in Scopus \(1\)](#)

[Request Permissions](#)
 [Order Reprints](#)
(100 minimum order)

Linked Articles





Article Info

Summary **Full Text** Tables and Figures References Supplementary Material

Summary

Background

Children of preschool age often have episodes of virus-associated wheeze, and research assessing efficacy of corticosteroids for paediatric wheeze exacerbations is inconclusive.

Methods

This non-inferiority, randomised, double-blind, placebo-controlled trial was to compare the efficacy of placebo versus oral prednisolone in children aged 24–72 months presenting with virus-associated wheeze at the paediatric emergency department of Princess Margaret Hospital in Perth, WA, Australia. Eligible participants were randomly assigned (1:1) using a computer-generated random number program to receive placebo or prednisolone (1 mg/kg per day) for 3 days. The primary outcome was total length of stay in hospital until ready for discharge. Following an analysis to test the hypothesis that placebo is non-inferior to prednisolone, a post-hoc superiority analysis was done to test the hypothesis that prednisolone was superior to placebo. A non-inferiority margin of 10% was used to establish non-inferiority. Efficacy analyses were on a modified intention-to-treat basis, whereby patients were excluded from the final efficacy analysis if consent was withdrawn, two doses of study drug were vomited, or paperwork was lost. All participants were included in safety analyses. This study is registered with the Australian and New Zealand Clinical Trials Registry, number ACTRN12612000394842.

Findings

Between June 11, 2012, and June 10, 2015, we screened 3727 patients for eligibility. 624 eligible patients were randomly assigned to treatment, and 605 patients were included in the modified intention-to-treat analysis (300 patients from the placebo group, 305 patients from the prednisolone group). The median length of stay until ready for discharge was longer in the placebo group (540 min [IQR 124–971]) than in the prednisolone group (370 min [121–709]); placebo was inferior to prednisolone. In the post-hoc superiority analysis of 605 patients, the unadjusted ratio of geometric mean for length of stay was 0.79 (95% CI 0.64–0.97; $p=0.0227$) for the prednisolone group relative to the placebo group. No serious adverse events were reported during the study or follow-up period. One child in the placebo group had a non-specific maculopapular rash, which resolved spontaneously. Two children (one from each group) were reported to be hyperactive during follow-up assessments.

Interpretation

Oral prednisolone had a clear benefit over placebo at reducing the length of stay in children presenting to a paediatric emergency department with virus-associated wheeze and was well tolerated.

Funding

Western Australian Department of Health.

COMMENT

Oral corticosteroids reduce length of hospital stay for preschool children with virus-associated wheeze

CORRECTIONS

Corrections

Related Clinics

< 1 2 >

Asthma

Popular Articles

Most Read Most Cited

Most read in *The Lancet Respiratory Medicine* within the past 30 days.

ARTICLES

Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

Vol. 5, No. 9

Published: August 16, 2017

[Open Access](#)

ARTICLES

Physiotherapy breathing retraining for asthma: a randomised controlled trial

Vol. 6, No. 1

Published: December 13, 2017

[Open Access](#)

REVIEW

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper

Vol. 6, No. 2

Published: November 15, 2017

ARTICLES

Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial

To read this article in full you will need to make a payment

Already registered? Please login.

[Login to existing account](#)

[Forgot password?](#)

Register

[Create a new account](#)

Payment Options

- **Purchase this article for \$31.50 USD**
 - Online access for 24 hours
 - PDF version can be downloaded as your permanent record

Subscribe to The Lancet Respiratory Medicine

Purchase a subscription to gain access to this and all other articles in this journal.

Options include:

The Lancet Choice

Access any 5 articles from The Lancet family of journals

- Full text and PDF access to 5 paywall articles of your choice
- Valid for 365 days from date of purchase
- [Find out more about The Lancet Choice](#)

Personal online only subscription

Institutional Access

Visit [ScienceDirect](#) to see if you have access via your institution.

Already a print subscriber?

[Claim online access](#)

Have a free trial code?

[Activate your free trial](#)

Published: February 21, 2018

CORRESPONDENCE

Diagnostic criteria for idiopathic pulmonary fibrosis

Vol. 6, No. 2

Published: February, 2018

The Lancet Journals

The Lancet
The Lancet Child & Adolescent Health
The Lancet Diabetes & Endocrinology
The Lancet Gastroenterology & Hepatology
The Lancet Global Health
The Lancet Haematology

The Lancet HIV
The Lancet Infectious Diseases
The Lancet Neurology
The Lancet Oncology
The Lancet Planetary Health
The Lancet Psychiatry
The Lancet Public Health
The Lancet Respiratory Medicine
EBioMedicine

Information & Support

About Us
Information for Authors
Information for Readers
The Lancet Careers
Customer Service
Contact Us
Privacy Policy
Terms and Conditions

Subscription

Your Account
Subscription Options
Existing Print Subscribers

Copyright © 2018 Elsevier Limited except certain content provided by third parties.

The Lancet is a trade mark of Elsevier Limited.

The Lancet.com website is operated by Elsevier Inc. The content on this site is intended for health professionals.

Cookies are set by this site. To decline them or learn more, visit our [Cookies page](#).

The Lancet demonstrates its commitment to accessibility by enabling access and optimising the experience for individuals with disabilities and impairments.